Mink Therapeutics Net Worth
Mink Therapeutics Net Worth Breakdown | INKT |
Mink Therapeutics Net Worth Analysis
Mink Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mink Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mink Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mink Therapeutics' net worth analysis. One common approach is to calculate Mink Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mink Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mink Therapeutics' net worth. This approach calculates the present value of Mink Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mink Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mink Therapeutics' net worth. This involves comparing Mink Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mink Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Mink Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mink Therapeutics' net worth research are outlined below:
| Mink Therapeutics is way too risky over 90 days horizon | |
| Mink Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (10.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mink Therapeutics currently holds about 29.85 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.88. | |
| Roughly 74.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Edgewise Therapeutics Trading Up 7.9 percent - Still a Buy - MarketBeat |
Mink Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mink Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mink Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Mink Therapeutics Target Price Consensus
Mink target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mink Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Strong Buy |
Most Mink analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mink stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mink Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMink Therapeutics Target Price Projection
Mink Therapeutics' current and average target prices are 19.80 and 52.50, respectively. The current price of Mink Therapeutics is the price at which Mink Therapeutics is currently trading. On the other hand, Mink Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Mink Therapeutics Market Quote on 22nd of July 2025
Target Price
Analyst Consensus On Mink Therapeutics Target Price
Know Mink Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mink Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mink Therapeutics backward and forwards among themselves. Mink Therapeutics' institutional investor refers to the entity that pools money to purchase Mink Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bnp Paribas Arbitrage, Sa | 2025-03-31 | 23.0 | Northwestern Mutual Wealth Management Co | 2025-03-31 | 18.0 | Game Plan Financial Advisors, Llc | 2025-03-31 | 16.0 | Hartland & Co | 2025-03-31 | 14.0 | Jones Financial Companies Lllp | 2025-03-31 | 1.0 | Captrust Financial Advisors | 2024-12-31 | 0.0 | Chilton Capital Management L P | 2024-12-31 | 0.0 | Hanson Mcclain Inc | 2025-03-31 | 0.0 | Jaffetilchin Investment Partners, Llc | 2024-12-31 | 0.0 | Vanguard Group Inc | 2025-03-31 | 23.7 K | Geode Capital Management, Llc | 2025-03-31 | 11.3 K |
Follow Mink Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 78.92 M.Market Cap |
|
Project Mink Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.89) | (1.98) | |
| Return On Capital Employed | 8.60 | 9.03 | |
| Return On Assets | (1.89) | (1.98) | |
| Return On Equity | 0.55 | 0.52 |
When accessing Mink Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mink Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mink Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Mink Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mink Therapeutics. Check Mink Therapeutics' Beneish M Score to see the likelihood of Mink Therapeutics' management manipulating its earnings.
Evaluate Mink Therapeutics' management efficiency
Mink Therapeutics has return on total asset (ROA) of (1.119) % which means that it has lost $1.119 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.3898) %, meaning that it created substantial loss on money invested by shareholders. Mink Therapeutics' management efficiency ratios could be used to measure how well Mink Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 9.03 in 2025, whereas Return On Tangible Assets are likely to drop (1.98) in 2025. At this time, Mink Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 7.3 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 5.4 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (5.19) | (4.93) | |
| Tangible Book Value Per Share | (5.19) | (4.93) | |
| Enterprise Value Over EBITDA | (2.52) | (2.65) | |
| Price Book Value Ratio | (1.34) | (1.41) | |
| Enterprise Value Multiple | (2.52) | (2.65) | |
| Price Fair Value | (1.34) | (1.41) | |
| Enterprise Value | 26.6 M | 25.3 M |
Understanding the management dynamics of Mink Therapeutics allows us to gauge its ability to sustain growth and profitability. This comprehensive analysis aids in determining the stock's value.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mink Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mink Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mink Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mink Therapeutics Corporate Filings
| 15th of July 2025 Other Reports | ViewVerify | |
8K | 14th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 30th of April 2025 Other Reports | ViewVerify |
Mink Therapeutics Earnings Estimation Breakdown
The calculation of Mink Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Mink Therapeutics is estimated to be -0.455 with the future projection ranging from a low of -0.55 to a high of -0.36. Please be aware that this consensus of annual earnings estimates for Mink Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.55 Lowest | Expected EPS | -0.36 Highest |
Mink Therapeutics Earnings Projection Consensus
Suppose the current estimates of Mink Therapeutics' value are higher than the current market price of the Mink Therapeutics stock. In this case, investors may conclude that Mink Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Mink Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2025 | Current EPS (TTM) | |
| 3 | 62.9% | -0.7 | -0.455 | -2.46 |
Mink Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Mink Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Mink Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Mink Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Mink Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Mink Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Mink Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Mink Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Mink Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-06-12 | 2025-03-31 | -0.15 | -0.7 | -0.55 | 366 | ||
2025-03-18 | 2024-12-31 | -0.08 | -0.62 | -0.54 | 675 | ||
2024-11-14 | 2024-09-30 | -0.0801 | -0.05 | 0.0301 | 37 | ||
2024-08-08 | 2024-06-30 | -0.1 | -0.0727 | 0.0273 | 27 | ||
2024-05-14 | 2024-03-31 | -0.15 | -0.11 | 0.04 | 26 | ||
2024-03-21 | 2023-12-31 | -0.15 | -0.16 | -0.01 | 6 | ||
2023-11-09 | 2023-09-30 | -0.18 | -0.15 | 0.03 | 16 | ||
2023-08-10 | 2023-06-30 | -0.2 | -0.18 | 0.02 | 10 | ||
2023-05-11 | 2023-03-31 | -0.24 | -0.17 | 0.07 | 29 | ||
2023-03-21 | 2022-12-31 | -0.21 | -0.23 | -0.02 | 9 | ||
2022-11-03 | 2022-09-30 | -0.23 | -0.19 | 0.04 | 17 | ||
2022-08-09 | 2022-06-30 | -0.24 | -0.18 | 0.06 | 25 | ||
2022-05-10 | 2022-03-31 | -0.21 | -0.23 | -0.02 | 9 | ||
2022-03-18 | 2021-12-31 | -0.41 | -0.18 | 0.23 | 56 | ||
2021-11-29 | 2021-09-30 | -0.2 | -0.59 | -0.39 | 195 | ||
2021-09-01 | 2021-06-30 | -0.28 | -0.21 | 0.07 | 25 | ||
2021-06-30 | 2021-03-31 | 0 | -0.2106 | -0.2106 | 0 | ||
2021-03-31 | 2020-12-31 | 0 | -0.2106 | -0.2106 | 0 | ||
2020-12-31 | 2020-09-30 | 0 | -0.157 | -0.157 | 0 | ||
2020-09-30 | 2020-06-30 | 0 | -0.157 | -0.157 | 0 | ||
2020-06-30 | 2020-03-31 | 0 | -0.1798 | -0.1798 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.1798 | -0.1798 | 0 |
Mink Therapeutics Corporate Management
| Kimberly Ha | Head Relations | Profile | |
| Joy Zhou | Vice CMC | Profile | |
| Marcus Dijk | Chief Officer | Profile | |
| Heather Boussios | General Officer | Profile |
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.